Related Experiment Video
Updated: Jul 6, 2026
09:17
In Vivo Luminal Measurement of Distension-Evoked Urothelial ATP Release in Rodents
Published on: September 7, 2022
Ketorolac effectively inhibits ureteral contractility in vitro
C Charles Wen1, Tawnya L Cary Coyle, Travis J Jerde
1Division of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Journal of Endourology
|March 8, 2008
Summary
Ketorolac effectively reduces ureteral contractility in a dose-dependent manner, showing significant inhibition at concentrations between 1 nM and 1 microM. This suggests local ketorolac use may help manage kidney stone pain while minimizing adverse effects.
Area of Science:
- Pharmacology
- Urology
- Nephrology
Background:
- Ketorolac is used for painful symptoms of urinary stones.
- Gastric and renal adverse effects limit its use.
- It acts as a nonselective cyclooxygenase inhibitor, potentially reducing ureteral contractions and inflammation.
Purpose of the Study:
- To confirm ketorolac's inhibition of ureteral contractility.
- To establish a dose-response relationship for ketorolac's effectiveness.
- To identify an effective dosage range for managing renal colic.
Main Methods:
- Porcine ureter strips were used in organ tissue baths with Krebs buffer.
- Spontaneous contractility was measured using force displacement transducers.
- Tissues were exposed to a concentration-response curve of ketorolac (0.1 nM-10 microM) and analyzed.
Main Results:
- Ketorolac demonstrated dose-dependent inhibition of ureteral contractility.
- Significant reduction in contractility was observed starting at 1 microM ketorolac.
- Inhibition ranged from 18.2% at 0.1 nM to 98.3% at 10 microM after 90 minutes.
Conclusions:
- Ketorolac concentration-dependently inhibits ureteral contractility between 1 nM and 1 microM.
- Local administration of ketorolac at these doses may be beneficial for stone management.
- This approach could help limit the risk of adverse effects associated with systemic ketorolac use.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:28Renal Drug Excretion: Tubular Secretion
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
01:15Drug Elimination by Renal Route: Tubular Secretion
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:22Drug Elimination by Renal Route: Tubular Reabsorption
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...